ArticleActa neuropathologica2020
Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.
Article in Acta neuropathologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- A Cauda Equina Neuroendocrine Tumor with Tyrosine Hydroxylase Expression.Endocrine pathology · 2026Article
- Clinicoradiological Features and Surgical Outcomes of Cauda Equina Neuroendocrine Tumors: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Cauda equina neuroendocrine tumour of the filum terminale: a rare cause of persistent sciatica.Oxford medical case reports · 2025Article
- Intradural paragangliomas in the cauda equina region: a case report and literature review.Frontiers in oncology · 2025Article
- Cauda Equina Neuroendocrine Tumors with Ganglioneuromatous Elements are Best Classified as Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor (COGNET).Endocrine pathology · 2024Article
- Concurrent multiple cerebral cavernous malformations and cauda equina paraganglioma: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Cauda equina neuroendocrine tumor: a report of three cases and review of the literature with focus on differential diagnosis and postoperative management.Neurosurgical review · 2024Review
- Review
- Cauda equina neuroendocrine tumors show biological features distinct from other paragangliomas and visceral neuroendocrine tumors.Virchows Archiv : an international journal of pathology · 2023Article
- Unraveling the functional consequences of a novel germline missense mutation (R38C) in the yeast model of succinate dehydrogenase subunit B: insights into neurodegenerative disorders.Frontiers in molecular neuroscience · 2023Article
- A 56-year-old woman with back pain and lower limbs weakness.Brain pathology (Zurich, Switzerland) · 2022Article
- Neuropathologic features of central nervous system hemangioblastoma.Journal of pathology and translational medicine · 2022Review
- TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.Acta neuropathologica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paragangliomas/pheochromocytomas are rare neuroendocrine tumors that arise from the adrenal gland or ganglia at various sites throughout the body. They display a remarkable diversity of driver alterations and are associated with germline mutations in up to 40% of the cases. Comprehensive molecular profiling of abdomino-thoracic paragangliomas revealed four molecularly defined and clinically relevant subtypes. Paragangliomas of the cauda equina region are considered to belong to one of the defined molecular subtypes, but a systematic molecular analysis has not yet been performed. In this study, we analyzed genome-wide DNA methylation profiles of 57 cauda equina paragangliomas and show that these tumors are epigenetically distinct from non-spinal paragangliomas and other tumors. In contrast to paragangliomas of other sites, chromosomal imbalances are widely lacking in cauda equina paragangliomas. Furthermore, RNA and DNA exome sequencing revealed that frequent genetic alterations found in non-spinal paragangliomas-including the prognostically relevant SDH mutations-are absent in cauda equina paragangliomas. Histologically, cauda equina paragangliomas show frequently gangliocytic differentiation and strong immunoreactivity to pan-cytokeratin and cytokeratin 18, which is not common in paragangliomas of other sites. None of our cases had a familial paraganglioma syndrome. Tumors rarely recurred (9%) or presented with multiple lesions within the spinal compartment (7%), but did not metastasize outside the CNS. In summary, we show that cauda equina paragangliomas represent a distinct, sporadic tumor entity defined by a unique clinical and morpho-molecular profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.